103 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
41 Recruiting Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Condition: Graft Versus Host Disease
Interventions: Dietary Supplement: Lactobacillus rhamnosus GG;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Supportive Care;   Masking: Open Label
Number Enrolled: 68
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02144701
42 Not yet recruiting Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer;   Recurrent Ovarian Cancer;   Recurrent Endometrial Cancer
Interventions: Drug: BKM120;   Drug: Nabpaclitaxel
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 60
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02117817
43 Not yet recruiting Akt/ERK Inhibitor ONC201 in Treating Patients With Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: Akt/ERK inhibitor ONC201
Study Type: Interventional
Phase: Phase 1
Funder Type: Other / NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 30
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02250781
44 Not yet recruiting High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: ipilimumab;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 82
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02203604
45 Recruiting Radiation Therapy in Treating Women With Early Stage Breast Cancer
Condition: Breast Cancer
Interventions: Radiation: External beam boost;   Radiation: whole breast irradiation
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 150
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT00909909
46 Recruiting Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: choline magnesium trisalicylate;   Drug: idarubicin;   Drug: cytarabine;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 40
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02144675
47 Not yet recruiting Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
Condition: Graft Versus Host Disease
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Supportive Care;   Masking: Open Label
Number Enrolled: 20
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02203578
48 Recruiting AML Therapy With Irradiated Allogeneic Cells
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: fludarabine phosphate;   Drug: cytarabine;   Biological: donor lymphocytes;   Other: laboratory biomarker analysis;   Drug: G-CSF
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 50
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02105116
49 Recruiting A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Condition: Resectable Pancreatic Cancer
Intervention: Drug: LDE-225
Study Type: Interventional
Phase: Phase 0
Funder Type: Other / NIH / Industry
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 20
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01694589
50 Unknown  Second Curettage in Treating Patients With Persistent Non-Metastatic Gestational Trophoblastic Tumor
Condition: Gestational Trophoblastic Tumor
Interventions: Other: laboratory biomarker analysis;   Procedure: conventional surgery
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 66
Gender: Female
Age Groups: Child / Adult / Senior
NCT Number: NCT00521118
51 Recruiting Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 1520
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT00936390
52 Recruiting Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)
Condition: Advanced, Metastatic Breast Cancer
Interventions: Drug: LEE011;   Drug: Letrozole;   Drug: LEE011 Placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 500
Gender: Female
Age Groups: Child / Adult / Senior
NCT Number: NCT01958021
53 Recruiting Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy;   Procedure: videothoracoscopy
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment
Number Enrolled: 1258
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT00499330
54 Recruiting Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation;   Radiation: selective external radiation therapy
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 154
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01055197
55 Recruiting Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: pentostatin
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 110
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT00074282
56 Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 100
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01164228
57 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexuality and Reproductive Issues;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Other: quality-of-life assessment
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 780
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT01414608
58 Recruiting Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: recombinant interferon alfa-2b;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 88
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01708941
59 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Crossover Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 523
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01886872
60 Recruiting A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant;   Drug: BKM120;   Drug: BKM120 matching placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 420
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT01633060

First Page    Show previous page of results Previous Page (21-40) Studies Shown (41-60) Next Page (61-80) Show next page of results    Last Page
Indicates status has not been verified in more than two years